Inactive Instrument

Highlights Verseon Corp

Equities

USU9221J1098

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Verseon Gains US Patent Protection for Compounds That Could Eliminate Bleeding Risks of Current Anticoagulants	01-24	CI
Verseon Corporation Reports Earnings Results for the Half Year Ended June 30, 2019	30/09/19	CI
Verseon Corporation Reports Earnings Results for the Full Year Ended December 31, 2018	28/06/19	CI
Verseon Showcases Candidates for Next-Generation Diabetic Eye Disease Drugs	04/06/19	CI
Verseon Corporation Presents Preclinical Efficacy Data for the First Development Candidate for Clinical Trials in Their Diabetic Eye Disease Program at ARVO 2019	30/04/19	CI
Verseon Corporation Announces First Participants Receive Verseon PRrecision Oral AntiCoagulant in Phase I Trial	04/02/19	CI
Verseon Corporation Unveils Transformative Blockchain Technology for Tokenized Securities	18/09/18	CI
Verseon Commences Phase I Trial for Precision Oral Anticoagulant VE-1902	13/09/18	CI
Verseon Corporation Provides Interim Report Charts Progress of Development Programs as it Submits Phase I Protocol for Precision Anticoagulant	14/08/18	CI
Verseon Corporation Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2018	08/08/18	CI
Verseon Corporation Submits Phase I Protocol for VE-1902	18/07/18	CI
Verseon Corporation Announces Consolidated Earnings Results for the Year Ended December 31, 2018	25/06/18	CI
Verseon Preparing for Anticoagulant Phase I Trial	14/06/18	CI
Verseon Presents New Preclinical Data on Its Novel Class of Precision Oral Anticoagulants	07/06/18	CI
Verseon Presents New Efficacy Results on Oral Diabetic Macular Edema Drug Candidate at Vision and Ophthalmology Conference	02/05/18	CI
Verseon Corporation Presents Anticancer Agents Targeting Multidrug Resistant Tumors At Cancer Research Conference	18/04/18	CI
Verseon Corporation Presents Second Anticoagulant Candidate for Clinical Trials Presented at AHA 2017	15/11/17	CI
Verseon Corporation Presents Anticancer Agents for Multidrug Resistant Tumors at Bio-Europe 2017	08/11/17	CI
Verseon Corporation Announces Consolidated Earnings Results for the Six Months Ended June 30, 2017	25/09/17	CI
Verseon Reveals Preclinical Data on Novel Drug Candidates to Treat Diabetic Macular Edema	26/06/17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Verseon Corp

Equities

USU9221J1098

Highlights

Filters